Current companies
Likvor
Normal Pressure Hydrocephalus (NPH) is a significantly underdiagnosed condition with dementia-like symptoms. Even though up to 80% of the NPH population get better after surgery, only about 20% get the correct treatment. Lack of reliable diagnostics is one reason for this undertreatment.
Likvor offers a patented and CE certified system that helps caregivers to diagnose the condition and follow-up treatment results by measuring the dynamics of the spinal fluid in the brain.
The company has clients in six countries in Europe and had a revenue of 3.7 MSEK in 2017. Consumables account for an increasing share of the revenue. The market is growing and ageing populations around the world drives market demand.
Learn more or become a member for complete information and invitations to company presentations. For company information in English please contact us.
Lipigon Pharmaceuticals
Lipigon develops orphan drugs for people with lipid disorders and other cardiometabolic risk factors. The company’s main program targets the disease HoFH.
Large medical need. Today’s drugs are not sufficiently efficient, and lack of treatment may cause cardiovascular diseases already at the age of 20-30 years.
Short time to clinical trials. Lipisense has been tested in animal models with promising results. Initial test of toxicity and tolerability has been completed without remarks. The company targets clinical phase 1 studies already in 2020.
Large market. The total market for drugs targeting HoFH is estimated to 1,500 million dollars per year.
Learn more or become a member for complete information and invitations to company presentations. For company information in English please contact us.
Sciety is a digital investment network
Sciety combines medical and business competence to select promising growth companies in the life science sector. We give you the opportunity to invest in unlisted companies within digital health, medical technology and more.
Qualified companies
Sciety takes care of selection and vetting, and manages the complete investment process. We offer investment opportunities in companies with the potential to give return on investment and make a difference.
Straightforward to invest
As a member, you will find all investment information online and you will also be invited to meet with the companies at our investor lunches.
Selling the share
Invest online and free of charge. You will own your shares directly in the companies and join their expansion. We focus on companies with clear exit plans.
News
New venture at Sciety – develops drugs for diseases caused by high levels of blood lipids
Lipid imbalances does not only cause common diseases such as diabetes and cardiovascular diseases but also various rare diseases. The pharma company Lipigon is specialised in diseases caused by lipid…
Läs merSciety raises new capital to MedTech company in neurology and cancer
CARTANA raised almost 10 MSEK in a share issue that was fully subscribed at the end of September. The company has developed reagents for analysing tissue samples in drug development…
Läs merInvest with us
Sciety gives members the opportunity to invest in unlisted growth companies with the potential to give return on investment and make a difference. We specialise in the life science sector.